

December 12, 2024



PDRadiopharma Inc.

## PDRadiopharma Inc. Releases 'Report Creation Support Software' for Amyloid PET scans.

*\*This release is an English translation of “アミロイドPET 検査レポートの作成支援ソフトウェアリリースのお知らせ”, with a priority given to Japanese for content and interpretation.*

TOKYO, JAPAN – December 12, 2024 - PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo) announces that it will release 'Report Creation Support Software' (hereafter referred to as 'the Software') for Amyloid PET scans on December 18, 2024.

The Software is a dedicated tool to assist in creating reports for Amyloid PET scans conducted by using “AMYViD® Injection”※1.

### Advantages of the Software:

- The software assists in creating reports for Amyloid PET scans.
- The report can display the patient's Amyloid PET images side-by-side with typical images (positive / negative) and indicate key points to focus on.
- The created report can be used for information sharing among healthcare professionals and as explanatory material for patients.

The software will be distributed upon request from medical institutions using AMYViD® Injection.

By actively advancing solutions that support precise diagnosis and treatment, we are committed to improving dementia care, supporting the society of healthy longevity, and bringing meaningful assistance to patients, their families, and the broader community affected by dementia.

※1 Generic name: Florbetapir (18F). Florbetapir (18F), labeled with radioactive fluorine (18F), is a PET imaging agent developed to visualize amyloid beta plaques in the human brain. It received its first manufacturing and marketing approval in Japan in December 2016 as a “Flexible Dose™ formulation,” distinct from conventional radiopharmaceuticals. Amyvid and AMYViD are registered trademarks of Avid Radiopharmaceuticals, Inc.

### **About PDRadiopharma**

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit [www.pdradiopharma.com](http://www.pdradiopharma.com)

Inquiries:

PDRadiopharma Inc.

Contact: Akiko Murakami, General Affairs

Email: [s-info-hq@pdradiopharma.com](mailto:s-info-hq@pdradiopharma.com)